You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
This book focuses on the influence of sex and gender in migraine, presenting new insights in basic science as well as their clinical relevance. As migraine is roughly three times more common in women than in men, and also highly depends on hormonal milestones – such as menarche, menstruation, pregnancy and menopause – particular attention is devoted to the role of female sex hormones in this disease. The first chapters present general data on gender-related differences in migraine such as epidemiology, comorbidities and related risks. Furthermore, while several chapters focus on the role of female sex hormones in migraine-triggering mechanisms at a basic scientific level (e.g. cranial circulation), ample attention is also paid to the clinical relevance of such mechanisms and to the best clinical treatment for migraine patients. As the first book entirely devoted to this topic, it will be of interest to researchers and practitioners in the fields of neurology, internal medicine, endocrinology, physiology and pharmacology.
Intended to promote a more appropriate and modern therapeutic approach to migraine management, this book is the first to deal with monoclonal antibodies in this context. Authored by the most respected migraine experts from around the globe and drawing on the lessons learned in both clinical trials and clinical practice, it reviews the current state of knowledge on this important therapeutic innovation, which has produced impressive data in randomized controlled trials, and the efficacy and safety of which have been confirmed in day-to-day real-world use. Given its scope, the book will appeal to a broad range of specialists, including pharmacologists, clinical pharmacologists, neurologists and internists, but also to residents and medical students.
Headache disorders are among the most common disorders of the nervous system. They are pandemic and, in many cases, they are recurrent and can accompany the patient for the whole life. These disorders impose a substantial burden on headache sufferers, on their families and on society: the individual impact is measured by the frequency and severity of attacks, while the societal burden is measured in terms of loss of activity at work and school as well as of costs for the health system. As a matter of facts, headaches are ranked in the top ten, and maybe the top five, causes of disability worldwide: they are therefore extraordinarily common. Population-based studies have mostly focused on mig...
Published in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development.
This book is designed to focus on the role of Calcitonin Gene-Related Peptide (CGRP) in health and disease. This peptide, originally discovered in the 1980s as a sensory neuropeptide with cardiovascular effects, is now known to play a distinct role in the pain processing of migraine. The various chapters address the origin, localization and function of CGRP and its receptor in the peripheral nervous system, in the cardiovascular system, and in other tissues and organs. Further attention is paid to the drug discovery pathway where recent findings show the beneficial effect of small molecule antagonists of the CGRP receptors for the relief of the migraine attack and of monoclonal antibodies against CGRP or the CGRP receptor for migraine prevention.
Headache syndromes rank amongst the most common presenting symptoms in general practice and neurology, affecting up to 15% of the adult population. Part of the Oxford Textbooks in Clinical Neurology series, the Oxford Textbook of Headache Syndromes provides clinicians with a definitive resource for diagnosing and managing patients with primary and secondary forms of headaches, either as isolated complaints or as part of a more complex syndrome. Split into 7 key sections with 59 chapters, this comprehensive work discusses the scientific basis and practical management of headache syndromes in a logical format. Each chapter is written by international experts in neurology who share their research and extensive experience by providing a wealth of practical advice for use in clinical situations. In addition, all content is up-to-date and chapters incorporate discussions on the latest International Classification of Headache Disorders 3rd edition when relevant.
A Simon & Schuster eBook. Simon & Schuster has a great book for every reader.
This book on migraine is the first machine-generated scientific book in medicine published by Springer Nature, and reflects a new publication format which focuses on literature reviews: state-of-the-art computer algorithms were applied to select relevant sources from Springer Nature journal articles, rearrange them in a topical order, and provide short summaries of these articles. The result is the auto-summarization of current texts, organized by means of a similarity-based clustering routine in coherent chapters and sections. The human intervention of a world-renowned expert in this field grants the scientific soundness and appropriate organization of the contents identified. The AI-based ...